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Abstract: The last 12 months have seen the beginning of a new era in the treatment options available for patients with metastatic 
cutaneous melanoma, a disease previously characterised by its poor prognosis and limited treatment options. Two mechanistically 
diverse agents have now demonstrated an overall survival benefit in different patient subgroups and further clinical trials are ongoing 
with emerging single agents and novel combinations. The first agent to demonstrate an overall survival benefit was the CTLA-4 anti-
body, ipilimumab, illustrating the importance of the immune system and immunomodulation in melanoma tumorigenesis. The second 
group of agents to show a survival benefit were the selective BRAF inhibitors, vemurafenib and GSK2118436, in patients who are 
BRAF V600 mutation positive. In addition, in the same BRAF mutant patient population, MEK inhibitors also show promising results 
and are currently under investigation in later stage trials. Although ipilimumab, BRAF and MEK inhibitors are just passing through the 
clinical trials arena, their use will rapidly become more widespread. Along with their significant clinical benefits, there are also unique 
adverse events related to these agents. Although the majority are mild and can be managed with supportive treatment, some toxicities 
require special management strategies. We outline up-to-date clinical development and management guidelines for ipilimumab, as well 
as the BRAF and MEK inhibitors.
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Introduction
Malignant  cutaneous  melanoma  is  the  sixth  most 
common cancer in the UK with an annual incidence 
that is increasing more rapidly than any of the top ten 
cancers in males and females.1 The age-standardised 
incidence rate in the UK is 9–12 per 100 000 popula-
tion compared to 30–40 per 100 000 population in 
Australia/New Zealand. Although the least common 
skin cancer, cutaneous melanoma is the most life-
threatening with metastases present in 10%–15% of 
patients  at  diagnosis.2  Chemotherapy,  usually  with 
dacarbazine  or  temozolimide,  has  been  the  main-
stay of firstline treatment despite the reported overall 
survival (OS) rates of only 6–10 months and limited 
clinical benefit.3,4 It is only recently that advances in 
immunotherapy and agents targeting specific genetic 
aberrations in the mitogen-activated protein kinase 
(MAPK) pathway have dramatically improved out-
comes in advanced cutaneous melanoma. While stim-
ulating the immune system via T-cell activation to 
control tumour growth has demonstrated clinical ben-
efit in an unselected group of melanoma patients,5,6 
so far the benefit of the BRAF and MEK targeted 
agents is confined to the BRAF V600 mutant popu-
lation  alone.7,8  Furthermore,  compared  to  standard 
chemotherapy, the adverse events require specialised 
management  in  a  multidisciplinary  team,  particu-
larly the immune related adverse events associated 
with ipilimumab. Increased awareness and cautious 
management is required to reduce the impact of these 
side-effects on the patient, increase quality of life and 
prevent treatment related mortality.
Ipilimumab
Ipilimumab is a fully human monoclonal antibody 
directed  against  cytotoxic  T-lymphocyte  antigen-4 
(CTLA-4). CTLA-4 and CD28 are two proteins that 
are exported to the surface of T cells after immune 
cell activation and balance the stimulation and inhibi-
tion of T cell proliferation and activation. CTLA-4 
exerts an inhibitory effect on further cell prolifera-
tion whereas CD28 is a costimulator of T cell prolif-
eration and involved in IL-2 production.9 By binding 
to  the  CTLA-4  T-cell  receptor,  ipilimumab  blocks 
its inhibitory effect and potentiates cytotoxic T-cell 
activation.10
Pre-clinical  studies  demonstrated  that  injec-
tion of anti-CTLA-4 antibodies into mouse models 
could stimulate the rejection of murine tumours in 
colon,  ovarian  and  fibrosarcoma  models.11,12  Early 
clinical studies demonstrated that the mean half-life 
was 14.7 days and that there was no apparent cor-
relation between plasma concentrations or clearance 
with tumour response or toxicity. Clearance was not 
affected by renal or hepatic function.13
The early phase I/II studies in the metastatic mela-
noma setting demonstrated response rates in the order 
of 4.1%–15.7% with median OS between 8.5 months 
and 17.1 months.14,15 Interestingly, some patients had 
sustained tumour responses over 25 months.16 There 
also  appeared  to  be  a  dose-response  relationship 
demonstrated  in  some  studies14,16  but  this  relation-
ship was by no means absolute, as some patients with 
prolonged  disease  control  had  no  related  toxicity, 
while other patients with toxicity did not demonstrate 
  clinical benefit.
The pivotal phase 3 trial demonstrated an improve-
ment  in  OS  in  human  lymphocyte  antigen  (HLA-
A*0201)-positive  patients  with  previously  treated 
metastatic melanoma randomised to either a vaccine 
gp100 versus gp100 in combination with ipilimumab 
(3 mg/kg at weeks 1, 4, 7, 10 with or without reinduc-
tion) versus ipilimumab alone.5 Gp100 is a synthetic 
peptide  cancer  vaccine  comprising  HLA-A*0201-
  restricted  peptides  derived  from  the  melanosomal 
protein glycoprotein 100, that appeared to improve 
the efficacy of high-dose interleukin-2 in metastatic 
melanoma  and  provided  a  rationale  for  its  use  to 
potentiate  the  efficacy  of  ipilimumab.17 There  was 
an improvement in median OS from 6.4 months with 
gp100 alone compared to 10.0 months with gp100 
plus ipilimumab and 10.1 months with ipilimumab 
alone. Importantly the 1- and 2-year survival rates 
improved  to  45.6%  and  23.5%  respectively  with 
  ipilimumab  compared  to  25.5%  and  13.7%  with 
gp100 alone. There was no additional effect of gp100 
to ipilimumab.
More recently, Study 024 compared firstline treat-
ment with dacarbazine (850 mg/m2 every 3 weeks 
for  22  weeks)  plus  placebo  versus  dacarbazine 
plus ipilimumab (10 mg/kg at weeks 1, 4, 7, 10) in 
patients with unresectable stage III or stage IV met-
astatic    melanoma.6  Again,  there  was  an  improve-
ment in median OS from 9.1 months to 11.2 months 
(HR 0.72, 95% CI 0.59–0.87, P = 0.0009) with an 
increase in the 1 year (36.3% vs. 47.3%), 2 years Novel treatments for metastatic cutaneous melanoma
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(17.9% vs. 28.5%) and 3 years (12.2% vs. 20.8%) 
  survival  rate    respectively.  There  was  no  clinically 
significant difference in median progression free sur-
vival, measuring 2.6 months and 2.8 months respec-
tively  (P  =  0.006).  Although  the  disease  control 
rate was similar (30.2% vs. 33.2%), the duration of 
response was markedly improved, from 8.1 months to 
19.3 months in patients who received ipilimumab.
A phase 3 trial is in development to compare ipili-
mumab at 3 mg/kg versus ipilimumab at 10 mg/kg, as 
well as ipilimumab in combination with other agents 
to help determine its optimal dose and placement in 
the treatment of metastatic melanoma.18
Significance of the MAPK Pathway
Improved understanding of the genetic heterogeneity 
in melanoma, the detection of oncogenic aberrations 
and the ability to target these changes, are factors that 
have further expanded the treatment options available 
for this disease.
The  MAPK  pathway  is  particularly  important 
in  melanoma  tumorigenesis  and  regulation  of  cell 
growth, proliferation and differentiation.   Activation 
of  the  Raf  Sarcoma  (RAS)  family  of  GTPases  by 
growth factors or by RAS mutation then drives activa-
tion of the RAF kinase family (ARAF, BRAF, CRAF) 
with  subsequent  phosphorylation  and  activation  of 
MEK kinases (MEK 1 and 2) and extracellular sig-
nal-regulated kinases (ERK 1 and 2).19 This leads to 
phosphorylation of the Erythroblast Transformation 
Specific (ETS) protein family, nuclear transcription 
factor activation and finally to cell-cycle progression 
and regulation of normal cellular functions, including 
apoptosis and survival. MAPK pathway activity is 
key for normal cell function but abnormal activation, 
through mutations and other aberrations have been 
implicated in a number of cancer sub-types, including 
melanoma, colorectal cancer and borderline ovarian 
cancer, among others.19
Genetic  aberrations  in  the  MAPK  pathway  are 
present in over 80% of cutaneous melanomas, involv-
ing abnormalities in RAS, RAF, MEK and ERK.20 The 
most common mutation appears to be in the activating 
v-raf murine sarcoma viral oncogene homologue B1 
(BRAF), occurring in 36%–59% of primary melano-
mas and 42%–66% of metastatic melanomas21–23 and 
has been characterised as an oncogenic mutation.19,24 
The  most  common  somatic  mutation  is  found  at 
V600E in exon 15 in 66%–90% of BRAF mutant 
melanomas.23,25,26 This is a point mutation in DNA 
(1799T-.A) resulting in a single amino-acid substi-
tution at Valine 600 to Glutamic acid in the activating 
segment, which leads to elevated kinase activity com-
pared with BRAF wild type, stimulated phosphoryla-
tion of downstream endogenous ERK and subsequent 
cellular proliferation and survival.19,27
The  V600  K  mutation  has  been  reported  in 
7%–28.5% of patients with BRAF mutant metastatic 
melanoma23,25,28,29 and involves two point mutations 
(GTG to AAG) with a lysine for valine substitution. 
Other non-V600E mutations have also been reported 
and will become increasingly relevant in interpreta-
tion of current and future clinical trials.
The presence of a BRAF mutation is a demonstrated 
poor prognostic factor with a strong association with 
inferior outcome in the metastatic setting.21,30,31
selective BRAF Inhibitors
Pre-clinical data demonstrated that selective BRAF 
inhibition results in growth arrest and induction of 
apoptosis in cell lines and xenograft models.32,33 The 
multiple tyrosine kinase inhibitor, sorafenib, was ini-
tially developed as a RAF inhibitor and was studied 
in some of the earlier clinical trials of RAF inhibition 
in metastatic melanoma. Despite encouraging phase 
2 results reporting disease stabilisation in a few unse-
lected advanced melanoma patients,34 further phase 
II  and  III  testing  in  the  first-line  and  second-line 
  setting respectively, failed to demonstrate clinically 
  significant activity.35,36
The  two  agents  that  have  demonstrated  signifi-
cant clinical benefit in melanoma are vemurafenib 
(PLX4032/RG 7204) and GSK2118436.
Vemurafenib is an orally available, highly potent, 
ATP competitive inhibitor of mutant BRAF. It is well 
absorbed after oral administration and is metabolized 
in the liver by CYP3A4. The half life is approximately 
57 hours and it reaches steady state after 15–22 days.37 
It is highly protein bound and is excreted primarily 
via the faeces.
The phase I trial of vemurafenib included a dose 
escalation phase (from 160 mg twice daily to 1120 mg 
twice daily) and dose extension phase (at 960 mg twice 
daily) and demonstrated a response rate (RR) of 69% 
(11 from 16 patients) and 81% (26 from 32 patients) 
respectively. The estimated median   progression-free Lemech and Arkenau
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survival (PFS) was more than 7 months with duration 
of response ranging from 2 months to over 18 months.38 
The BRAF in Melanoma 2 (BRIM-2) phase II study 
enrolled 132 patients with previously treated BRAF 
V600E mutant stage IV melanoma and demonstrated 
a RR of 53%, stable disease in a further 29%, median 
PFS of 6.7 months and OS at 6 and 12 months of 
77%  and  58%  respectively.39   Additionally  in  early 
2011, the phase III BRAF Inhibitor in Melanoma 3 
(BRIM3) trial included 675 BRAF V600E mutation 
positive metastatic melanoma patients and reported a 
significant improvement in OS in patients who were 
treated with vemurafenib compared to the standard 
firstline  chemotherapy  dacarbazine.7  The  RR  was 
48% versus 5% with a significant prolonged median 
PFS  of  5.3  months  in  the  vemurafenib  arm  com-
pared to 1.6 months on dacarbazine [HR 0.26 (95% 
CI 0.20–0.33) P , 0.0001]. At 6 months the over-
all    survival  was  84%  for  patients  on  vemurafenib 
compared to 64% for patients on dacarbazine with a 
63% relative risk reduction for death.
GSK2118436 is another ATP competitive, revers-
ible  inhibitor  of  mutant  BRAF V600E,  as  well  as 
V600D/K and V600G kinases. The phase I/II trial 
included 61 patients, 52 with BRAF mutant mela-
noma  and  V600E/D/K  mutations.  At  the  time  of 
reporting the RR was 60% (18 from 30 patients) and 
PFS 8.3 months at the recommended phase-II dose 
level of 150 mg twice daily.8 Pharmacokinetic stud-
ies indicated that peak plasma levels were reached 
after 2 hours and the half-life was 4–9 hours. At this 
phase II dose, the drug inhibited intratumoural phos-
phorylated ERK levels by .90%, indicating MAPK 
pathway suppression. In the dose expansion cohort 
of 20 melanoma patients, the overall RR was 77%. 
The majority of patients (77%) had a BRAF V600E 
mutation but 19% had a V600K mutation and the RR 
in this group was 44% (4 out of 9).
The dose-escalation phase also included a cohort 
of 10 patients with previously untreated brain metas-
tases who also demonstrated a significant response 
to treatment. Brain metastases decreased in size in 
9 out of 10 patients, correlating with extra-cranial 
response. This reduction ranged from a 20% to 100% 
decrease in size of metastases that were 3–15 mm in 
size prior to   treatment.40 Ongoing studies are assess-
ing GSK2118436 versus dacarbazine in previously 
untreated  patients  with  BRAF  mutant  advanced 
or  metastatic  melanoma,  as  well  as  a  study  of 
GSK2118436 in BRAF mutant metastatic melanoma 
to  the  brain.18  Both  these  studies  have  completed 
recruitment.
MEK Inhibitors
In addition to inhibiting BRAF signalling with selec-
tive BRAF inhibitors, there is good pre-clinical evi-
dence of anti-proliferative activity of MEK inhibitors 
in melanoma.41 Several inhibitors of the downstream 
checkpoint MEK are currently in development and 
phase 1–3 clinical trials are underway.
The earliest MEK inhibitors in preclinical and 
clinical  development  demonstrated  limited  clini-
cal  activity  and  included  PD98059,  UO126  and 
CI-1040.42  PD0325901,  a  structural  analogue  of 
CI-1040, was a second generation MEK inhibitor 
evaluated in phase I and II trials in metastatic cuta-
neous melanoma patients with some early evidence 
of response and disease stabilisation, but its further 
development  was  limited  by  toxicity,  particularly 
ocular toxicity.43 AZD6244 was another MEK inhib-
itor  to  show  small  numbers  of  response  and  dis-
ease stabilisation in melanoma patients;44 however 
failed to show any improvement in PFS compared 
to temozolomide in a randomised phase II trial.45 
  Single-agent clinical trials have not been pursued 
with this agent but phase 2 combination trials with 
dacarbazine,  docetaxel  and  temsirolimus  are  cur-
rently underway in BRAF mutant metastatic mela-
noma in the first-line setting.18
In contrast, the phase I/II study of the MEK inhibi-
tor GSK1120212showed good tolerability in the 162 
enrolled  patients,  predominantly  with  melanoma 
and pancreatic cancer. It has a half life of approxi-
mately 4.5 days and reaches steady state by day 15. 
There were 20 evaluable patients with BRAF mutant 
melanoma and at the recommended phase-II dose of 
2 mg once daily, RRs were 40% (8 from 20 patients) 
and a further 18% had stable disease (SD).46 Further 
single agent activity is being assessed in an ongoing 
  phase-III trial, randomising patients to GSK1120212 
versus first or second line chemotherapy.18
There is also pre-clinical and early clinical evi-
dence  that  the  combination  of  a  BRAF  and  MEK 
inhibitor  (GSK2118436  and  GSK1120212)  shows 
clinical activity in BRAF V600 mutant melanoma not 
only with a potential reduction in drug resistance but Novel treatments for metastatic cutaneous melanoma
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Table 1. Management of immune related adverse events from ipilimumab.
Skin toxicity Diarrhoea and enterocolitis Hepatitis
Supportive care Sunscreen 
Emollients 
Topical steroid cream 
+/- antibiotics
Diet modification 
Hydration 
Loperamide
If abnormal, monitor LFTs every 
3–7 days
Initiation of  
corticosteroids
Budesonide for prolonged G2 diarrhoea 
Methylprednisolone Iv for grade  
3/4 diarrhoea 
Slow wean of prednisone over  
4–6 weeks
Methylprenisolone Iv for ALT . 8 
xULN and bilirubin . 5 xULN 
prednisone for persistent Grade 
2 changes in LFTs or Grade 3 
changes (ALT . 5 xULN)
Other  
recommendations
Infliximab 
Consider TpN or surgical  
intervention
Mycophenolate mofetil 
Tacrolimus 
Infliximab 
Anti-thymocyte globulin
also with decreased toxicity.47 Resistance to BRAF 
  inhibition can be mediated by a number of different 
mechanisms  that  may  occur  upstream  (eg,  NRAS 
mutation),  or  downstream  (eg,  MEK  mutation)  of 
BRAF  along  the  MAPK  pathway,  as  well  as  via 
bypass signalling pathways through the PI3 K-AKT 
pathway.48–51 Addition of a MEK inhibitor to a BRAF 
inhibitor  may  thus  overcome  resistance  mediated 
by mechanisms downstream of BRAF. Preliminary 
results at doses of GSK2118436 150 mg twice daily 
and  GSK1120212  2  mg  daily  in  19  patients  have 
demonstrated  a  complete  response  rate  of  11%,  a 
total RR (CR + PR) of 74% and clinical benefit rate 
(CR + PR + SD) of 100%.47
Emerging New Toxicity Profiles 
and Recommended Management 
strategies
The  novel  mechanisms  of  action  of  these  agents 
confer clinically relevant toxicities requiring special 
management and screening strategies (Table 1). The 
corresponding Level of Evidence (Table 2) is also 
outlined.
Ipilimumab
The  adverse  effects  mediated  by  ipilimumab  are 
predominantly  immune  response  related.  The  first 
phase III trial reported all grade drug-related events 
in  80.2%  of  patients  including  expected  adverse 
events related to monoclonal antibodies such as ana-
phylaxis as well as immune related adverse events 
(irAEs) in the range of 60%.5 These irAEs covered 
a broad spectrum of systems; including dermatologic 
(pruritus in 17.6% and rash in 17.6%), gastrointesti-
nal (diarrhoea in 30.3% and colitis in 5.3%), hepatic 
(increase ALT in 0.8% and AST in 1.1%, autoim-
mune hepatitis in 0.5%) and endocrine (hypothy-
roidism,  hypopituitarism,  hypophysitis,  adrenal 
insufficiency, increase in serum thyrotropin level and 
decrease in serum corticotrophin level). There were 
seven of fourteen deaths that were associated with 
irAEs; 1 with grade 3 colitis and septicaemia, 4 with 
bowel perforation/  peritonitis, 1 with Guillain-Barre 
  syndrome and 1 with liver   failure. The higher grade 3 
and 4 irAEs are outlined in Table 3.
The adverse events in the phase III trial comparing 
ipilimumab and dacarbazine with dacarbazine alone 
were consistent with these findings (Table 3) and were 
higher in the ipilimumab plus dacarbazine arm, with 
predominantly dermatologic (pruritus in 26.7% and 
rash in 22.3%), gastrointestinal (diarrhoea in 32.8% 
and colitis in 4.5%), hepatic (increase alanine amin-
otransferase in 29.1% and aspartate aminotransferase 
in 26.7%, autoimmune hepatitis in 1.6%) and endo-
crine events.6 There was a lower rate of grade 3 or 4 
diarrhoea and colitis but a higher rate of transaminitis 
in this study compared to earlier single agent studies. 
Importantly, no patient died as a result of complica-
tions of immune related hepatitis or enterocolitis.
Dermatologic Toxicity
Dermatologic  toxicity  is  the  most  common  irAE 
reported  (all  grades  up  to  43.5%  and  grade  3/4 
1%–3%) and generally appears after 2–4 weeks of 
  treatment. Symptomatic   management is   recommended Lemech and Arkenau
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with    non-irritant  moisturisers  and  body  wash,  low 
dose topical corticosteroids (  betamethasone 0.1% or 
hydrocortisone 1%) or urea-based topical therapies 
with antipruritic agents.52 Sun avoidance and the use 
of broad-spectrum sunscreen is recommended pro-
phylactically. The use of cool   compresses and oral 
anti-histamines may also assist with   symptomatic relief 
of pruritus. Higher dose topical corticosteroids may be 
required for more severe rash (hydrocortisone 2%) and 
oral prednisone at 1 mg/kg/day should be initiated if 
there is no improvement or if the rash is   complicated by 
  dermal ulceration, necrotic, bullous or haemorrhagic 
Table 3. Immune related adverse events from lpilimumab in phase 2 and 3 trials.
patient number  
(n =)
phase III6 
Ipi and DTIc 
(Ipi at 10 mg/kg) 
250
phase-III5 
Ipi monotherapy  
(3 mg/kg) 
131
phase-II49 
Ipi monotherapy 
different doses 
217 (71 each at 3 mg/kg 
and 10 mg/kg)
All grade irAE % 
[Grade 3, 4%]
77.7 
[31.6, 10.1]
61.1 
[12.2, 2.3]
65 at 3 mg/kg [7] 
70 at 10 mg/kg [25]
Dermatologic % 
[Grade 3, 4%]
43.5 
[1.5, 0]
45 at 3 mg/kg [1.5] 
46 at 10 mg/kg [4.2]
pruritus% 
 
rash 
vitiligo
26.7 [2.0, 0] 
 
22.3 [1.2, 0]
24.4 [0, 0] 
 
19.1 [0.8, 0] 
2.3 [0, 0]
21.3 at 3 mg/kg [1.4] 
32.4 at 10 mg/kg [2.8] 
23.9 at 3 mg/kg [1.4] 
22.5 at 10 mg/kg [0]
Gastrointestinal % 
[Grade 3, 4%]
29 
[7.6, 0]
32 at 3 mg/kg [2.8] 
39.4 at 10 mg/kg [15.5]
Diarrhoea % 
 
Colitis
32.8 [4.0, 0] 
 
4.5 [1.6, 0.4]
27.5 [4.6, 0] 
 
7.6 [5.3, 0]
25.3 at 3 mg/kg [1.4] 
39.4 at 10 mg/kg [14.0] 
5.6 at 3 mg/kg [1.4] 
5.6 at 10 mg/kg [2.8]
Endocrine % 
[Grade 3, 4%]
7.6 
[2.3, 1.5]
5.6 at 3 mg/kg [2.8] 
4.2 at 10 mg/kg [1.5]
Hypothyroid % 
Hypopituitarism 
Hypophysitis 
Adrenal insufficiency 
Increase thyrotropin 
Decrease corticotrophin
1.5 [0, 0] 
2.3 [0.8, 0.8] 
1.5 [1.5, 0] 
1.5 [0, 0] 
0.8 [0, 0] 
1.5 [0, 0.8]
Hepatic % 
[Grade 3, 4%]
3.8 
[0, 0]
0 at 3 mg/kg 
2.8 at 10 mg/kg [2.8]
Increase ALT % 
Increase AST 
Hepatitis
29.1 [15.0, 5.7] 
26.7 [13.8, 3.6] 
1.6 [1.2, 0]
1.5 [0, 0] 
0.8 [0, 0] 
0.8 [0, 0]
Abbreviations: irAE, immune related adverse event; DTIC, dacarbazine; Ipi, ipilimumab; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
Table 2. NHMrC levels of evidence.
Level Intervention
I A systematic review of level II studies
II A randomised controlled trial
III-1 A pseudorandomised controlled trial (ie, Alternate allocation or other method)
III-2 A comparative study with concurrent controls (non-randomised experimental trial, cohort study, 
case-control study, interrupted time series with a control group)
III-3 A comparative study without concurrent controls (nistorical control study, two or more single arm 
study, interrupted time series without a parallel control group)
Iv Case series with either post-test or pre-test/post-test outcomes)Novel treatments for metastatic cutaneous melanoma
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  manifestations.53  Scalp  lesions  can  be  particularly 
troublesome for patients and may benefit from use of 
low dose corticosteroid-containing   shampoo or topi-
cal cold tar (Level of Evidence II).
Gastrointestinal Toxicity
Diarrhoea  is  the  second  most  common  toxicity, 
affecting up to 30% of patients, and the most com-
mon toxicity with grade 3 or 4 symptoms, reported 
in 7.6% with monotherapy at 3 mg/kg, 5.6% with 
DTIC and up to 15% of patients at higher doses of 
ipilimumab.5,6,54 Interestingly and taking into account 
the difficulties with cross trial comparison and the 
greater  experience  with  management,  ipilimumab 
at  10  mg/kg  in  combination  with  dacarbazine  in 
the phase 3 trial compared to monotherapy in phase 
2 data seemed to be associated with less grade 3 and 
4 diarrhoea and colitis.6,55 Clinically, the average time 
of onset of diarrhoea was at 6–8 weeks, but can occur 
as early as 3 days post initiation of treatment with 
rapid progression to colitis,56 such that early multi-
disciplinary management is   crucial. Grade 1 and 2 
diarrhoea may be managed symptomatically on an 
outpatient basis with immediate initiation of loper-
amide  and  close  clinical  follow-up.  Modification 
of diet with small frequent meals, introduction of a 
BRAT diet (bananas, rice, apples, toast), ceasing lac-
tose containing products and maintaining fluid intake 
with electrolyte replacement is recommended (Level 
of Evidence II).
For prolonged grade 1–2 and higher grade diar-
rhoea,  oral  and/or  IV  corticosteroids  are  essential 
(Level of Evidence II). For grade 1–2 diarrhoea last-
ing  over  5  days,  oral  budesonide  should  be  com-
menced starting at 9 mg daily (as a single dose or in 3 
divided doses) for up to 8 weeks, with a tapering dose 
over the final 2–4 weeks of treatment.56 Alternatively, 
oral prednisone can be used at 1 mg/kg/day and simi-
larly, have a slow taper. Endoscopy should be con-
sidered at this stage and clinicians should be aware 
there can be rapid progression from grade 1 diarrhoea 
to severe colitis, requiring urgent hospital admission 
and management. Persistent grade 1–2 diarrhoea after 
oral corticosteroids or the development of grade 3–4 
diarrhoea, should prompt urgent endoscopy, and initi-
ation of high dose intravenous (IV) steroids.56   Further 
t  reatment with ipilimumab should be with-held (Level 
of Evidence IV).
In  a  recent  study  of  198  patients  treated  with 
ipilimumab, 41 patients developed grade 3/4 diarrhoea 
of which 39 patients were endoscopically diagnosed 
with enterocolitis and histopathological findings were 
of neutrophilic inflammation with cryptitis in 46%, 
lymphocytic inflammation in 15% or combined neu-
trophilic and lymphocytic inflammation in 38%.57
In this scenario, recommended treatment is high 
dose IV methylpredisolone (2 mg/kg for 1–2 weeks) 
followed by a 30 to 45-day taper of prednisone start-
ing at 60 mg per day. A rapid reduction in steroid 
dose should be avoided and may risk the develop-
ment of recurrent symptoms and the need for escala-
tion of care.56 An alternative steroid regimen is with 
intravenous dexamethasone 4 mg every 6 hours, ini-
tially over 7 days.57 At this stage, a more rapid dose 
reduction over 17 days was also reviewed. Out of 34 
patients treated with this regimen, 12 patients had 
refractory enterocolitis with 5 patients not respond-
ing within 7 days and 7 patients relapsed after taper-
ing the steroid dose. Four of these were treated with 
infliximab with a rapid and durable response (Level 
of Evidence IV).
Infliximab (5 mg/kg IV) is recommended if there 
is no response within one week of steroid initiation, or 
if there is relapse following steroid reduction, unless 
there are other contraindications such as bowel perfo-
ration or sepsis. An additional dose at a 2 week inter-
val may be required (Level of Evidence II).
Small numbers of patients have been treated with 
an  alternative  regimen  including  the  initiation  of 
infliximab at the onset of grade 2 diarrhoea, with a 
second dose 2 weeks later, and given in combination 
with  mesalamine,  loperamide  and  hydrocortisone 
enemas.58 4 out of 6 patients were treated success-
fully with this regimen, avoiding the use of systemic 
steroids.
Good supportive care during this initial 1–2 week 
period  is  essential  with  view  to  early  initiation  of 
total parenteral nutrition (TPN) if necessary and sur-
gical review if diarrhoea is not settling. The need for 
surgical intervention with formation of a diverting 
ileostomy or a partial/complete colectomy has been 
reported in some cases with the potential for clinical 
benefit if medical management fails.59
In all symptomatic cases, infective aetiology should 
be excluded by means of stool culture, microscopy 
for cells, ova, cyst and parasites and   investigation for Lemech and Arkenau
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clostridium difficile toxin. Polymerase chain reaction 
for noravirus or other pathogens may also be neces-
sary depending on suspected exposure.
Prophylactic  budesonide  for  the  prevention  of 
gastrointestinal toxicity has been studied but did not 
reduce the incidence of grade 2–4 diarrhoea and is not 
recommended60 (Level of Evidence II).
Importantly,  early  initiation  of  diarrhoea  treat-
ment guidelines (DTGs) has been shown to reduce 
bowel perforation and colectomy rates, drug-related 
diarrhoea and serious gastrointestinal irAEs by up to 
50%61 (Level of Evidence III-2).
Hepatic Toxicity
Hepatotoxicity occurs in up to 29% of patients with 
grade 3 and 4 toxicity reported in up to 15% with the 
combination of ipilimumab and dacarbazine and 0.8% 
with  ipilimumab  alone  (at  3  mg/kg  dose),  usually 
between 6–8 weeks after commencing ipilimumab.5,6 
Progressive liver disease, viral hepatitis and alterna-
tive drug toxicity should be excluded. Investigation 
of  immune  and  non-immune  hepatotoxicity  should 
included hepatitis serology, CMV and EBV serology, 
anti-nuclear antibodies (ANA), antimitochondrial anti-
bodies,  liver-pancreas-specific  antigen,  liver-  kidney 
microsomes  and  smooth  muscle  antigen  (SMA)  as 
well  as  consultation  with  a  hepatologist52 (Level of 
Evidence II).
For grade 2 changes in liver function tests (LFTs, 
Table 4), ipilimumab should be with-held and LFTs 
measured daily for 3 days, with the initiation of oral 
steroid therapy (prednisone 1 mg/kg/day) if there is 
no improvement after 48–72 hours.52 This should be 
continued for a minimum of 30 days and LFTS moni-
tored closely until they normalise. Grade 3 changes 
should also prompt the initiation of a course of oral 
corticosteroids and ipilimumab should be discontin-
ued62 (Level of Evidence II).
If the ALT rises . 8 xULN and bilirubin . 5 xULN, 
high dose steroid therapy is recommended with intra-
venous methylprednisonlone 2 mg/kg daily. If there 
is no improvement in transaminases after 48 hours, 
the  addition  of  mycophenolate  mofetil  1  g  twice 
daily is recommended.56 After a further 5–7 days, 
tacrolimus  0.10–0.15  mg/kg/day  is  recommended 
with measurement of target trough levels. Treatment 
with infliximab 5 mg/kg as a single dose may also 
be required in refractory and severe cases (Level of 
Evidence II).
Successful therapy of fulminant hepatitis has also 
been reported with antithymocyte globulin (1.5 mg/kg 
given at 4 intervals over 2 weeks) rather than inflix-
imab.  This  case  demonstrated  rapid  improvement 
in hepatic transaminases and synthetic function in a 
patient refractory to corticosteroids and mycopheno-
late63 (Level of Evidence IV).
endocrinopathies
Although  uncommon,  the  endocrinopathies  are 
another  emergent  toxicity  induced  by  ipilimumab 
Table 4. CTCAE grading for diarrhoea, changes in liver function tests and visual changes.
Grade 1 Grade 2 Grade 3 Grade 4
Diarrhoea Increase of ,4 stools  
per day over baseline;  
mild increase in ostomy  
output compared  
to baseline
Increase of 4–6 stools  
per day over baseline;  
moderate increase in  
ostomy output compared  
to baseline
Increase of $7 stools per day  
over baseline; incontinence;  
hospitalization indicated;  
severe increase in ostomy  
output compared to baseline;  
limiting self care ADL
Life-threatening 
consequences; 
urgent intervention 
indicated
Liver function tests
Bilirubin  
AST/ALT
ULN – 1.5 xULN 
ULN – 3.0 xULN
1.5 xULN – 3.0 xULN 
3.0 xULN – 5.0 xULN
3.0 xULN – 10 xULN 
5.0 xULN – 20 xULN
.10 xULN 
.20.0 xULN
visual  
changes
Asymptomatic or mild  
symptoms; clinical or  
diagnostic observations  
only; intervention  
not indicated
Moderate; minimal,  
local or noninvasive  
intervention indicated; 
limiting age-appropriate  
instrumental ADL
Severe or medically  
significant but not  
immediately sight-threatening; 
Hospitalization or prolongation  
of existing hospitalization 
indicated; disabling;  
limiting self care ADLs
Sight-threatening 
consequences; 
urgent intervention 
indicated; 
blindness (20/200  
or worse) in the  
affected eye
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase.Novel treatments for metastatic cutaneous melanoma
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and  may  include  hypopituitarism,  hypophysitis, 
  hypothyroidism and adrenal insufficiency.5
Physicians  should  be  alerted  by  symptoms  of 
headache, visual field changes, fatigue, nausea, vom-
iting, fever, hypotension, arrhythmias and electrolyte 
abnormalities. As these symptoms are non-specific, 
other potential causes including disease progression, 
syndrome of inappropriate ADH secretion (SIADH) 
and  sepsis  need  to  be  excluded.  Examination  of 
the hypothalamic-pituitary axis should be assessed 
including thyroid stimulating hormone, free T4/T3, 
adrenocorticotropic  hormone,  serum  cortisol  +/- 
short  synachten  test,  luteinizing  hormone,  follicle-
stimulating  hormone,  testosterone  and  prolactin.15 
MRI of the head with the hypophysis and visual field 
testing should be performed and early endocrinologist 
involvement is recommended. Symptoms of hypo-
physitis usually develop after 6 weeks of treatment 
and MRI may show thickening of the hypophyseal 
stalk52,64 (Level of Evidence II)
If suspicious of an adrenal crisis, stress dose IV 
steroids (dexamethasone 4 mg every 6 hours) should 
be administered as well as gonadal and thyroid hor-
mone replacement as required and with the consulta-
tion of an endocrinologist. Longer term management 
will involve tapering the steroids over a minimum of 
4 weeks; however many patients will require steroid 
replacement for longer periods or life-long if there 
is  inadequate  recovery  of  hypophyseal  function. 
  Ongoing  monitoring  of  hormone  substitution  and 
assessment of laboratory endocrine studies is required. 
Ipilimumab may be re-instituted after resolution of 
grade 1–2 endocrinopathies but as the risk of further 
complications is unknown, it is not recommended in 
more severe cases (Level of Evidence II). Recently 
however,  patients with  hypophysitis  with  the  need 
for hormone replacement have been retreated with 
ipilimumab without worsening side effects15 (Level 
of Evidence IV).
Others
Other  immune  related  complications  have  been 
described. A recent case report described a case of anti-
CTLA-4 antibody-induced lupus nephritis, confirmed 
on renal biopsy and electron microscopy.65   Antibodies 
to  double-stranded  DNA  were  also  detected  and 
regressed  after  ipilimumab  was  withdrawn  and  the 
patient was treated with predisone (1 mg/kg daily).
Ophthalmological side effects have been reported 
in less than 1% of treated patients, in some studies, in 
association with diarrhoea and colitis. These events 
usually  resolve  within  a  week  but  treatment  with 
steroid eye drops may be required and systemic corti-
costeroids in more severe cases.16
Neurological toxicity such as Guillain-Barre syn-
drome, sensory or motor neuropathy or myasthenia 
gravis have been reported in less than 1% of patients.52 
Other non-inflammatory causes need to be assessed 
and neurological consultation may assist with consid-
eration of EMG and/or nerve conduction studies. For 
grade 3 and 4 symptoms, hospitalisation, IV steroids, 
IV  immunoglobulin  or  other  immunosuppressants 
may be required and ipilimumab should be ceased.
selective BRAF Inhibitors
The selective BrAF inhibitors are 
generally well tolerated with low  
rates of grade 3 and 4 toxicities
The most common adverse events with vemurafenib 
recently described in BRIM-3 included grade 2 and 3 
arthralgias (18% and 3%), rash (10% and 8%), photo-
sensitivity (12% grade 2 or 3), fatigue (11% and 2%), 
cutaneous  squamous-cell  carcinoma  (SCC,  12%), 
keratoacanthoma (2% and 6%), nausea (7% and 1%) 
and diarrhoea (5% and ,1%).7 Dose interruption and 
modification were required in 38% of patients.
GSK2118436 is also very well tolerated with simi-
lar side effects reported in the phase I/II trial including 
skin changes (all grades 37%; grade 3 (G3):1 patient), 
low grade cutaneous SCC (2 pts/3%), headache (all 
grades 19%, G3:1 pt), nausea (18% G1), fatigue (15% 
G1) and vomiting (all grades 13%, G2:4).8 Although 
the majority of side effects are similar between the 
two  BRAF  inhibitors,  vemurafenib  was  associated 
with photosensitivity in up to 30% of patients (12% 
grade 2 or 3) while pyrexia is reported in 15% (2% 
grade 3) on GSK2118436.
Interestingly, the BRAF and MEK inhibitor com-
bination (GSK2118436 and GSK1120212) not only 
demonstrated a potential reduction in drug resistance 
but also a lower incidence of rash, BRAF-induced 
hyperproliferative  skin  lesions  and  SCC.47  There 
was a lower incidence of skin rash (all grade 25%, 
grade $ 3 2%) compared to single agent toxicities as 
well as a lower incidence of hyperproliferative skin 
lesions (1 from 109 patients with cutaneous SCC). Lemech and Arkenau
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  Recommendations for the skin rash,   photosensitivity 
and diarrhoea are similar to that described for the 
MEK  inhibitors  below.  Management  of  fever  and 
SCC is discussed in detail.
Fever
Fever secondary to the BRAF inhibitors, primarily 
GSK2118436, can usually be managed with support-
ive care but thorough assessment is recommended to 
exclude a source of sepsis. For fever up to 39 degrees 
(grade 1), treatment with paracetamol every 8 hours 
is  recommended,  alternating  with  ibuprofen  every 
8 hours if needed. For fever between 39–40 degrees 
(grade  2),  the  BRAF  inhibitor  should  be  ceased, 
investigation to exclude sepsis should be performed 
and hospitalisation may be required. In case of tem-
perature over 40 degrees (grade 3), hospitalisation 
and rehydration are recommended with further inves-
tigation for a source of sepsis. Care should be taken 
with choice of antibiotics to avoid drug interactions 
(Level of Evidence II).
squamous cell carcinoma
As evidenced with both selective BRAF inhibitors 
though less commonly with GSK2118436,66 there is 
an increased incidence of cutaneous SCC. This usu-
ally develops between weeks 2 to 14 and is hypoth-
esised  to  be  due  to  upstream  RAS  mutations  in 
pre-existing SCC skin lesions, which may occur in 
approximately 15% of patients. Selective inhibition 
of downstream BRAF can lead to CRAF signalling 
by this mutant RAS with subsequent development of 
SCCs.67,68 The majority of these SCCs are keratoa-
canthoma type, well-differentiated with no metastatic 
potential and can be treated with surgical excision.38 
Patients should have a thorough skin examination at 
baseline and be monitored regularly during treatment. 
At the development of any new skin lesions, a der-
matologist should be consulted and excision arranged 
(Level of Evidence II).
MEK Inhibitors
Early results from the phase 1/2 study of the MEK 
inhibitor, GSK1120212, demonstrated that the most 
common  adverse  events  were  an  acneiform  rash 
(all grade 85%; $grade 3: 2%), usually on the face, 
torso and arms; diarrhoea (all grade 48%; .grade 3: 
2%), fatigue (all grade 37%; $grade 3 7%), nausea 
(all grade 20%; $grade 3: 0), vomiting (all grade 
24%, $grade 3: 2%). Less common events included 
left  ventricular  systolic  dysfunction  (9  from 
162  patients),  central  serous  retinopathy  (CSR: 
3 from 162 patients, at dose levels higher than 2 mg 
daily) and retinal vein occlusion (RVO: 1 from 162 
at 2 mg daily).46 Among the cases of left ventricu-
lar systolic dysfunction, few were considered related 
to GSK1120212 and it was rarely symptomatic. All 
3  cases  of  CSR  resolved  upon  drug  interruption. 
RVO was not reversible, however the patient experi-
enced significant improvement in visual acuity after 
intraocular bevacizumab treatment.69
A number of other early MEK inhibitor trials also 
demonstrated ocular toxicity with reports of visual 
disturbance,  including  halos,  spots  and  decreased 
acuity. This is discussed in detail below.
skin Rash
Prophylactic treatment to reduce the incidence of grade 
3–4 skin rash is recommended. Patients should avoid 
excess exposure to sunlight and use broad-spectrum 
sunscreen (containing titanium dioxide or zinc oxide) 
with a skin protection factor SPF $ 15. Alcohol-free 
emollient cream should be used on dry skin two to 
three times daily with a mild strength topical steroid 
(hydrocortisone cream 1%) once daily. Oral doxycy-
cline or minocycline is also recommended on the first 
day of treatment as part of the prophylactic regimen 
or topical antibiotics can be used if oral antibiotics 
cannot be tolerated (Level of Evidence II).
For moderate skin rash with pruritus or tender-
ness, topical steroids can be increased to hydrocorti-
sone cream 2.5% or triamcinolone cream 0.1% if the 
prophylactic measures are unsuccessful. In case of 
higher grade rash despite topical steroid treatment a 
dose reduction should be considered. For more severe 
symptoms with a significant impact on activities of 
daily living (ADL) and risk of super-infection, the 
drug should be ceased until the rash improves and a 
dermatologist should be consulted with consideration 
of oral steroids.
Other symptomatic measures that may assist with 
pruritus are the use of cool compresses and oral anti-
histamines. Paronychia should be treated with anti-
septic baths, local topical potent corticosteroids and 
oral  antibiotics  with  referral  to  a  dermatologist  or 
surgeon if no improvement is seen. Infected lesions Novel treatments for metastatic cutaneous melanoma
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should be assessed with bacterial and fungal cultures 
and treated with systemic agents as appropriate (Level 
of Evidence II).
Diarrhoea
For  grade  1  and  2  (Table  4)  diarrhoea,  both  non-
pharmacological and pharmacological measures are 
recommended as discussed previously. For grade 2 
diarrhoea, the drug should be with-held until symp-
toms have resolved to baseline or grade 1, at which 
point the agent may be reintroduced. If grade 1 or 2 
diarrhoea persists for 48 hours despite dietary modifi-
cation and the introduction of loperamide, second line 
agents including octreotide, budesonide or codeine-
based treatment may be required.
If there is clinical deterioration or grade 3 or 4 
diarrhoea, the MEK inhibitor should be ceased and 
if restarted, will require a dose reduction. Hospital-
ization, IV rehydration and regular loperamide are 
recommended.  Severe  dehydration  should  prompt 
the  addition  of  octreotide.  Colonoscopy  should  be 
performed to further assess for colitis and exclude 
an infective cause. Antibiotic cover including fluoro-
quinolones is recommended if grade 3 or 4 diarrhoea 
persists beyond 24 hours, if there is fever or grade 3 
or 4 neutropaenia (Level of Evidence II).
Visual changes
Ocular toxicity, particularly RVO and CSR, have been 
reported with a number of MEK inhibitors in devel-
opment. The phase I study with PD0325901 demon-
strated RVO in 3 from 66 patients, particularly with 
the continuous schedule, and this limited further trials 
beyond phase II.70 After the first two cases of RVO, 
there was a protocol amendment to exclude patients 
with  glaucoma,  intraocular  pressure  .21  mmHg 
or any other significant abnormality on ophthalmic 
examination by an ophthalmologist. An ophthalmic 
examination was required every cycle for visual acu-
ity,  visual  field  examination,  intraocular  pressure, 
external eye exam and dilated fundoscopy at baseline 
and before each cycle. On retrospective analysis, pre-
disposing factors for retinopathy included hyperten-
sion, diabetes, hypercholesterolemia and glaucoma. 
The occurrence of RVO on the continuous schedule 
raised the possibility that the ocular toxicity was asso-
ciated with prolonged and/or high levels of pERK 
suppression. The phase II study with this agent on an 
intermittent schedule had similar exclusion criteira 
and although there was grade I/II visual disturbance 
with blurred vision, halo vision and diplopia, there 
were no cases of RVO.71
The  phase  I  study  of  AZD6244  demonstrated 
transient  and  reversible  blurred  vision  in  7  from 
57 patients (12%) but no evidence of CSR nor RVO 
on ophthalmologic examination.44 AZD6244 is ten-
fold less potent than PD0325901 and it was hypoth-
esised that the ocular side-effects may correlate with 
the extent of MEK inhibition.72
In  the  pre-clinical  and  phase  I/II  studies  with 
GSK1120212, there have also been reports of RVO 
and CSR. RVO was reported in rabbit models and in 
one case in man;47 however it was unclear whether 
this case was an adverse drug reaction or an adverse 
event due to a prothrombotic malignant state. CSR 
has been reported in 3 cases from 162 patients treated 
with GSK1120212 and changes were reversible on 
drug cessation in all cases.
The phase III study comparing GSK1120212 to 
chemotherapy  in  subjects  with  advanced  or  meta-
static  BRAF  mutant  melanoma  excludes  patients 
with  a  history  of  RVO  or  CSR  and  patients  with 
predisposing factors such as uncontrolled glaucoma 
or  ocular  hypertension,  uncontrolled  hyperten-
sion,  uncontrolled  diabetes  mellitus,  or  history  of 
hyperviscosity  or  hypercoagulability  syndromes.73 
  Ophthalmologic  examination  is  mandated  at  study 
entry and includes indirect and direct fundoscopy as 
well as tonometry. Patients with any visible retinal 
pathology considered a risk factor for RVO or CSR 
are also excluded, including evidence of new optic 
disc cupping or intraocular pressure .21 mmHg.
Knowledge  of  the  assessment  required  prior  to 
administration of the MEK inhibitors will be essential 
as the use of these agents increases.
Current  recommendations  outline  that  patients 
who are asymptomatic or with mild symptoms and 
clinical changes should have ophthalmology review 
to  determine  if  there  are  changes  consistent  with 
RVO, in which case the drug should be discontinued. 
If there is CSR, the agent should be ceased until signs 
and symptoms have resolved and then can restart at a 
lower dose. If ophthalmologic examination is normal, 
the agent should be continued.
For grade 2 or 3 visual changes (Table 4), with mod-
erate to severe symptoms and limiting instrumental or Lemech and Arkenau
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self care activities of daily living, the agent should be 
ceased and urgent ophthalmology review obtained. If 
there is no RVO nor CSR, the agent should be ceased 
until symptoms have resolved to grade 1 or less, and 
can be restarted at a lower dose. For grade 4 visual 
changes that are sight-threatening, the agent should be 
permanently discontinued. CSR is reversible on drug 
discontinuation. RVO may require novel therapy with 
intraocular anti-VEGF therapy with the guidance of 
an ophthalmologist47 (Level of Evidence II).
Place in Therapy
The treatment paradigm for metastatic melanoma is 
changing with a number of active agents now avail-
able for treatment of this disease. Challenges exist not 
only in the optimal choice of agents for these patients 
but also in the timely and aggressive management 
of associated toxicities. Particularly with the BRAF 
and MEK inhibitors, the duration of benefit is often 
short-lived as resistance develops. Understanding of 
both primary and secondary resistance mechanisms is 
key to novel drug development and future clinical tri-
als both of single agent and combination therapies.48 
As  discussed,  understanding  of  the  importance  of 
the MAPK pathway in melanoma tumorigenesis and 
resistance pathways has already led to novel combi-
nation strategies and further such trials are underway 
and in development.18
There are also ongoing early clinical trials of vemu-
rafenib in combination with ipilimumab, particularly 
as understanding increases as to how BRAF inhibi-
tion  effects  immune  response  and  T-cell    function. 
BRAF inhibition has been shown to improve recog-
nition by antigen-specific T cells and increase intra-
tumoural and peritumoural lymphocytes shortly after 
drug    initiation.  Interestingly,  patients  who  develop 
resistance to BRAF inhibition demonstrate a decrease 
in  intratumoural  and  peritumoural  lymphocytes.74 
Compared to MEK inhibitors, BRAF inhibitors also 
seem to preserve T-cell function.75 Together, this early 
data provides a rationale for the combination of ipili-
mumab and BRAF inhibition.
Importantly, there are a number of overlapping tox-
icities with these agents, particularly diarrhoea and skin 
rash, and optimal management of these will need to be 
developed concurrent with testing clinical efficacy.
Thus, there remain many challenges in the treat-
ment of patients with metastatic melanoma – how to 
best treat patients without a BRAF mutation, how to 
  overcome resistance mechanisms that develop to BRAF 
and MEK inhibition and how to best combine immune 
and targeted therapy to optimise patient outcome.
conclusion
The  availability  of  novel  agents  targeting  immune 
system modulation and specific genetic aberrations 
in  metastatic  melanoma  has  given  hope  to  those 
patients, who up to recent times, had limited treat-
ment options. As outlined above, there are a num-
ber of class specific emergent toxicities calling for 
heightened vigilance and prompt initiation of therapy. 
  Multidisciplinary management, education and aware-
ness of these toxicities across disciplines is essential. 
Due to the severity and rapid progression of these tox-
icities, some recommend that these agents should be 
delivered in specialist centres by oncologists familiar 
with their use.76 As the development of new oncologi-
cal agents accelerates, physicians need to familiarise 
themselves with the toxicities and their management 
and the availability of evidence-based guidelines is 
key. These and other guidelines provide an outline of 
the expected toxicities and management for the most 
common and potentially severe adverse events from 
these agents.
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